Whether use of non-calcium-containing phosphate binders versus calcium-containing phosphate binders improves outcomes for patients with chronic kidney disease is unclear. Now, new data from an open-label randomized controlled trial suggest that the non-calcium-containing phosphate binder sevelamer hydrochloride significantly improves survival compared to calcium carbonate in incident patients on haemodialysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Di Iorio, B. et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2013.03.023.
Dhingra, R. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 167, 879–885 (2007).
Ärnlöv, J. et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin. J. Am. Soc. Nephrol. 8, 781–786 (2013).
Covic, A. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol. Dial. Transplant. 24, 1506–1523 (2009).
Lynch, K. E., Lynch, R., Curhan, G. C. & Brunelli, S. M. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 620–629 (2011).
Cozzolino, M., Rizzo, M. A., Stucchi, A., Cusi, D. & Gallieni, M. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther. Adv. Chronic Dis. 3, 59–68 (2012).
Di Iorio, B., Bellasi, A. & Russo, D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin. J. Am. Soc. Nephrol. 7, 487–493 (2012).
Block, G. A., Raggi, P., Bellasi, A., Kooienga, L. & Spiegel, D. M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 71, 438–441 (2007).
St Peter, W. L., Liu, J., Weinhandl, E. & Fan, Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 51, 445–454 (2008).
Bernard, L., Mendelssohn, D., Dunn, E., Hutchison, C. & Grima, D. T. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J. Med. Econ. 16, 1–9 (2013).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Covic, A., Voroneanu, L. Epic battles in the phosphate-binder wars—the last episode?. Nat Rev Nephrol 9, 497–498 (2013). https://doi.org/10.1038/nrneph.2013.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.149
